Lin W, Li C, Xu N, Watanabe M, Xue R, Xu A, et al. Dual-functional PLGA nanoparticles co-loaded with indocyanine green and resiquimod for prostate cancer treatment. Int J Nanomedicine. 2021;16:2775–87. https://doi.org/10.2147/IJN.S301552.

Article  PubMed  PubMed Central  Google Scholar 

van Die MD, Williams SG, Emery J, Bone KM, Taylor JM, Lusk E, et al. A placebo-controlled double-blinded randomized pilot study of combination phytotherapy in biochemically recurrent prostate cancer. Prostate. 2017;77:765–75. https://doi.org/10.1002/pros.23317.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell A, et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2018;73:834–44. https://doi.org/10.1016/j.eururo.2017.10.002

Article  PubMed  CAS  Google Scholar 

Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354–73. https://doi.org/10.1210/endrev/bnab002

Article  PubMed  PubMed Central  Google Scholar 

McDonald J, O’Brien J, Kostos L, Lawrentschuk N, Azad AA, Murphy D, et al. Systemic therapy in metastatic hormone-sensitive prostate cancer. Curr Opin Support Palliat Care. 2022;16:234–9. https://doi.org/10.1097/SPC.0000000000000622

Article  PubMed  Google Scholar 

Saunders PTK, Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic prospects. Cell. 2021;184:2807–24. https://doi.org/10.1016/j.cell.2021.04.041

Article  PubMed  CAS  Google Scholar 

Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021;18:739–62. https://doi.org/10.1038/s41585-021-00514-9

Article  PubMed  CAS  Google Scholar 

Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140:223–38. https://doi.org/10.1016/j.pharmthera.2013.07.003

Article  PubMed  CAS  Google Scholar 

Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al. B7-H3 as a therapeutic target in advanced prostate cancer [published correction appears in Eur Urol. Eur Urol. 2023;83:224–38. https://doi.org/10.1016/j.eururo.2022.09.004. 2023 Jun;83(6):e168-e169. https://doi.org/10.1016/j.eururo.2023.03.005].

Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365–80. https://doi.org/10.3978/j.issn.2223-4683.2015.05.02

Article  PubMed  PubMed Central  Google Scholar 

Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics. 2000;10:407–13. https://doi.org/10.1097/00008571-200007000-00004

Article  PubMed  CAS  Google Scholar 

Scariano JK, Treat E, Alba F, Nelson H, Ness SA, Smith AY. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate. 2008;68:1798–805. https://doi.org/10.1002/pros.20842

Article  PubMed  CAS  Google Scholar 

Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA. 2001;98:4904–9. https://doi.org/10.1073/pnas.081565498

Article  PubMed  PubMed Central  CAS  Google Scholar 

Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate. 1996;29:153–8. https://doi.org/10.1002/1097-0045(199609)29:33.0.co;2-5

Article  PubMed  CAS  Google Scholar 

van de Wijngaart DJ, Molier M, Lusher SJ, Hersmus R, Jenster G, Trapman J, et al. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J Biol Chem. 2010;285:5097–105. https://doi.org/10.1074/jbc.M109.039958

Article  PubMed  CAS  Google Scholar 

Thompson J, Saatcioglu F, Jänne OA, Palvimo JJ. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol. 2001;15:923–35. https://doi.org/10.1210/mend.15.6.0647

Article  PubMed  CAS  Google Scholar 

Hara T, Kouno J, Nakamura K, Kusaka M, Yamaoka M. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005;65:268–75. https://doi.org/10.1002/pros.20282

Article  PubMed  CAS  Google Scholar 

Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol. 2010;30:1243–53. https://doi.org/10.1128/MCB.01891-08

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem. 2002;277:38087–94. https://doi.org/10.1074/jbc.M203313200

Article  PubMed  CAS  Google Scholar 

Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 2002;62:5632–6.

PubMed  CAS  Google Scholar 

Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF-B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA. 2006;103:7264–9. https://doi.org/10.1073/pnas.0509808103

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12:1629–37. https://doi.org/10.1158/1535-7163.MCT-13-0027

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem. 2010;285:14980–9. https://doi.org/10.1074/jbc.M109.085696

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xu P, Wasielewski LJ, Yang JC, Cai D, Evans CP, Murphy WJ, et al. The immunotherapy and immunosuppressive signaling in therapy-resistant prostate cancer. Biomedicines. 2022;10:1778 https://doi.org/10.3390/biomedicines10081778.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nagireddy S, Qureshi R, Best J, Frech FS, Shah K, Soni Y, et al. Current treatment modalities targeting tumor microenvironment in castration-resistant prostate cancer. Adv Exp Med Biol. 2021;1329:295–323. https://doi.org/10.1007/978-3-030-73119-9_16

Article  PubMed  CAS  Google Scholar 

Wang F, Liu S, Liu F, Xu T, Ma J, Liang J, et al. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. Cancer Lett. 2023;568:216300 https://doi.org/10.1016/j.canlet.2023.216300

Article  PubMed  CAS  Google Scholar 

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559:363–9. https://doi.org/10.1038/s41586-018-0266-0

Article  PubMed  PubMed Central  CAS